NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adaptive T-cell Therapy (Adenovirus, Yeast, Fusion Protein Vaccine) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase: PHASE1
Conditions: Pancreatic Cancer
Sponsor: ImmunityBio, Inc.

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
1 
NANT PANCREATIC CANCER VACCINE: 
COMBINATION IMMUNOTHERAPY WITH HIGH-
AFFINITY NATURAL KILLER (haNK) CELL THERAPY 
IN SUBJECTS WITH PANCREATIC CANCER WHO 
HAVE PROGRESSED ON OR AFTER STANDARD-OF-
CARE THERAPY 
 
Study Number: 
QUILT-3.060 
IND Sponsor: 
NantKwest, Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Sponsor Contact:  
(For medical questions/emergencies) 
John H. Lee, MD 
Senior Vice President Adult Medical Affairs, 
NantKwest Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Email: John.Lee@Nantkwest.com 
Cell Phone: +1-605-610-6391 
 
Protocol Version 
Date 
Version 1 
15 September 2017 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
2 
STATEMENT OF COMPLIANCE 
This trial will be conducted in accordance with Good Clinical Practice (GCP) as described in the 
International Conference on Harmonization Guideline E6 (ICH E6) and in accordance with 
United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312) and the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
Institutional Review Board (IRB) prior to commencement.  The Principal Investigator will assure 
that no deviation from, or changes to the protocol will take place without prior agreement from 
NantKwest and documented approval from the IRB, except where necessary to eliminate an 
immediate hazard(s) to the trial participants.   
I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.   
 
Principal Investigator:  
 
Signed: _____________________________________ Date: ______________ 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
3 
PROTOCOL SYNOPSIS 
Name of Sponsor/Company: 
NantKwest, Inc. 
Name of Investigational Products:  
1. ALT-803 (recombinant human super agonist interleukin-15 (IL-15) complex [also known as 
IL 15N72D:IL-15RαSu/IgG1 Fc complex]) 
2. ETBX-011 (adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA [carcinoembryonic antigen]) 
3. GI-4000 (RAS yeast vaccine) 
4. haNK™, NK-92 [CD16.158V, ER IL-2], Suspension for Infusion (haNK™ for Infusion) 
Name of Approved Products: 
5. Avelumab (BAVENCIO® injection, for IV use) 
6. Bevacizumab (AVASTIN® solution for IV infusion) 
7. Capecitabine (XELODA® tablets, for oral use) 
8. Cyclophosphamide (Cyclophosphamide Capsules, for oral use; or Cyclophosphamide 
Tablets, USP) 
9. 5-Fluorouracil (5-FU; Fluorouracil Injection, for IV use only) 
10. Leucovorin (LEUCOVORIN Calcium for Injection, for IV or intramuscular [IM] use) 
11. Nab-paclitaxel (ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles 
for injectable suspension] [albumin-bound]) 
12. Omega-3-acid ethyl esters (LOVAZA® Capsules, for oral use) 
13. Oxaliplatin (ELOXATIN® injection for IV use) 
14. Stereotactic Body Radiation Therapy (SBRT) 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
4 
Name of Active Ingredients 
Investigational Products: 
1. ALT-803, recombinant human super agonist interleukin-15 (IL-15) complex (also known as 
IL 15N72D:IL-15RαSu/IgG1 Fc complex) 
2. Ad5 [E1-, E2b-]-CEA 
3. GI-4014 expressing mutations in RAS at codon 12 (G12V), and codon 61 (Q61R and Q61L); 
GI-4015 expressing mutations in RAS at codon 12 (G12C), and codon 61 (Q61R and Q61L); 
GI-4016 expressing mutations in RAS at codon 12 (G12D) and codon 61 (Q61R and Q61L); 
and GI-4020 expressing mutations in RAS at codon 12 (G12R) and codon 61 (Q61L and 
Q61H) 
4. NK92 [CD16.158V, ER IL2] cells 
Approved Products: 
5. Avelumab 
6. Bevacizumab 
7. Capecitabine 
8. Cyclophosphamide (anhydrous) 
9. Fluorouracil, USP 
10. Leucovorin (calcium salt) 
11. Paclitaxel, USP 
12. Omega-3-acid ethyl esters 
13. Oxaliplatin, USP 
14. Radiation 
Title of Study:  
NANT Pancreatic Cancer Vaccine: combination immunotherapy with high-affinity natural killer 
(haNK) in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy. 
Study Number: 
QUILT-3.060 
Study Phase: 
Phase 1b/2 (Simon’s two-stage optimal design). 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
5 
Study Objectives: 
Phase 1b 
• 
The primary objective is to evaluate the overall safety profile of the NANT pancreatic 
cancer regimen in subjects with pancreatic cancer who have progressed after standard-of-
care (SoC) therapy. 
• 
Secondary objectives are to obtain preliminary estimates of efficacy by objective 
response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of 
response (DOR), disease control rate (DCR), and quality of life (QoL) by patient-reported 
outcomes (PROs). 
• 
Exploratory objectives include the assessment of tumor molecular profiles (genomics, 
transcriptomics, and proteomics), therapy-induced changes in immune responses, and 
molecular changes in circulating tumor DNA (ctDNA) and RNA (ctRNA); and their 
correlations with subject outcomes. 
Phase 2  
• 
The primary objective is to determine the efficacy of the NANT pancreatic cancer 
regimen as assessed by ORR. 
• 
Secondary objectives are to obtain additional measures of safety and efficacy (PFS, OS, 
DOR, DCR, and QoL by PROs). 
• 
Exploratory objectives include the assessment of tumor molecular profiles, therapy-
induced changes in immune responses, and molecular changes in ctDNA and ctRNA; and 
their correlations with subject outcomes. 
Study Design: 
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in 
subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.  Phase 
2 will be based on Simon’s two-stage optimal design. 
Preliminary assessment of the safety of the treatment regimen will occur by an independent Data 
Safety Monitoring Committee (IDMC) and the NantKwest Safety Review Committee (SRC). 
Enrollment into the phase 1b portion will continue if data from the initial 3 subjects suggest that the 
combination therapy is tolerable. 
Treatment will be administered in two phases, an induction and a maintenance phase, as described 
below.  Subjects will continue induction treatment for up to 1 year. Treatment in the study will be 
discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not 
corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the 
subject’s best interest to continue treatment. Those who have a complete response (CR) in the 
induction phase will enter the maintenance phase of the study. Subjects may remain on the 
maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase 
until the subject experiences PD or unacceptable toxicity (not corrected with dose reduction), 
withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue 
treatment. The maximum time on study treatment, including both the induction and maintenance 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
6 
phases, is 2 years. 
Exploratory tumor molecular profiling will be conducted on samples collected prior to treatment on 
this study, at the end of the initial induction phase (8 weeks after the start of treatment), and during 
potential prolonged induction and maintenance phases (depending on response), as described in 
Section 6.4.1. Separate blood tubes will be collected every 4 weeks in the induction phase and every 
8 weeks in the maintenance phase during routine blood draws for exploratory immunology and 
ctDNA/ctRNA analyses, as described in Section 6.4.2 and Section 6.4.3, respectively. 
Tumors will be assessed at screening, and tumor response will be assessed every 8 weeks during the 
induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT), 
magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT of target and non-
target lesions in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 
1.1 and immune-related response criteria (irRC). 
Prospective Tumor Molecular Profiling 
Prospective tumor molecular profiling will be conducted to inform RAS mutational status and will be 
used to determine whether GI-4000 will be administered. All subjects will receive all other agents 
regardless of their tumor molecular profile. 
Prospective tumor molecular profiling will be performed on FFPE tumor tissue and whole blood 
(subject-matched normal comparator against the tumor tissue) collected at screening. More 
information on the collection of tumor tissue and whole blood is described in Section 6.4.1.2 and is 
similar to the collection of samples for the exploratory tumor molecular profiling. 
Subjects will receive GI-4000 if their tumor is positive for specific RAS mutations, as determined by 
whole genome sequencing. As described in Section 1.6.8.1, GI-4000 is 4 separate products from the 
GI-4000 series (GI-4014, GI-4015, GI- 4016, and GI-4020); each of these expresses a combination of 
mutated RAS oncoproteins. The specific RAS mutation will determine which GI-4000 product will be 
used for treatment (GI-4014 for G12V, GI-4015 for G12C, GI-4016 for G12D, GI-4020 for G12R or 
Q61H, and GI-4014, GI-4015, or GI-4016 for Q61L or Q61R).  
Induction Phase: 
The induction phase will consist of repeated 2-week cycles for a maximum treatment period of 1 year. 
The treatment regimen of ALT-803, avelumab, bevacizumab, cyclophosphamide, Ad5-based vaccine 
(ETBX-011), 5-FU/leucovorin, yeast-based vaccine (GI-4000), haNK, nab-paclitaxel, omega-3-acid 
ethyl esters, and oxaliplatin will be repeated every 2 weeks.  Concurrent stereotactic body 
radiotherapy (SBRT) will be given during the first four 2-week cycles.  Radiation will be 
administered to no more than 5 tumor sites using SBRT, as described in Section 5.1.5.1. 
The induction phase of study treatment will be conducted in accordance with the following dosing 
regimen: 
Daily: 
• 
Omega-3-acid ethyl esters (by mouth [PO] twice a day [BID] [3 × 1 g capsules and 
2 × 1 g capsules]) 
Day 1 every 2 weeks:  
• 
Bevacizumab (5 mg/kg IV) 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
7 
Days 1–5 and 8–12, every 2 weeks:  
• 
Cyclophosphamide (50 mg BID) 
Days 1, 3, 5, 8, 10 and 12, every 2 weeks: 
• 
5-FU (400 mg/m2 continuous IV infusion over 16 hours)   
• 
Leucovorin (20 mg/m2 IV bolus) 
Day 1 and 8, every 2 weeks:  
• 
Nab-paclitaxel (125 mg IV) 
• 
Oxaliplatin (40 mg/m2 IV) 
Day 5, 19, 33 (every 2 weeks for 3 doses then every 8 weeks thereafter):   
• 
ETBX-011 (5 × 1011 virus particles [VP]/vaccine/dose subcutaneously [SC]) 
• 
GI-4000 (40 yeast units [YU]/dose SC), 2 hours after administration of the Ad5-based 
vaccine 
Prospective tumor molecular profiling will determine whether GI-4000 will be 
administered, as described above. 
Day 8, every 2 weeks: 
• 
Avelumab (10 mg/kg IV over 1 hour) 
Day 8, 22, 36, 50 (every 2 weeks for 4 doses): 
• 
SBRT (not to exceed 8 Gy, exact dose to be determined by the radiation oncologist) 
Day 9, every 2 weeks:  
• 
ALT-803 (10 μg/kg SC 30 minutes prior to haNK infusion) 
Day 9 and 11, every 2 weeks:  
• 
haNK (2 x 109 cells/dose IV) 
Maintenance Phase: 
The duration of the maintenance phase will be up to 1 year following completion of the last treatment 
in the induction phase.  The maintenance phase will consist of repeated 2-week cycles. The treatment 
regimen of ALT-803, avelumab, bevacizumab, cyclophosphamide, capecitabine, Ad5-based vaccine 
(ETBX-011), yeast-based vaccine (GI-4000), haNK, nab-paclitaxel, and omega-3-acid ethyl esters 
will be repeated every 2 weeks. 
The maintenance phase of study treatment will be conducted in accordance with the following dosing 
regimen: 
Daily:  
• 
Omega-3-acid ethyl esters (PO BID [3 × 1 g capsules and 2 × 1 g capsules]) 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
8 
Day 1, every 2 weeks:  
• 
Avelumab (10 mg/kg IV over 1 hour)  
• 
Bevacizumab (5 mg/kg IV) 
• 
Nab-paclitaxel (125 mg IV) 
Days 1–5 and 8–12, every 2 weeks: 
• 
Capecitabine (650 mg/m2 PO BID) 
• 
Cyclophosphamide (50 mg BID) 
Day 2, every 2 weeks:  
• 
ALT-803 (10 µg/kg SC, 30 minutes prior to haNK infusion) 
• 
haNK (2 x 109 cells/dose IV)  
Day 5, every 8 weeks thereafter: 
• 
ETBX-011 (5 × 1011 VP/vaccine/dose SC) 
• 
GI-4000 (40 YU/dose SC), 2 hours after administration of the Ad5-based vaccine 
Prospective molecular profiling will determine whether GI-4000 will be administered, as 
described above. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
9 
Phase 1b 
Primary Endpoint: 
• 
Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded 
using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03. 
Secondary Endpoints: 
• 
ORR by RECIST Version 1.1 and irRC. 
• 
PFS by RECIST Version 1.1 and irRC. 
• 
OS. 
• 
DOR. 
• 
DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months). 
• 
QoL by PROs. 
Exploratory Endpoints: 
• 
Tumor molecular profiles and correlations with subject outcomes. 
• 
Therapy-induced changes in immune responses and correlations with subject outcomes. 
• 
Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. 
Phase 2 
Primary Endpoint: 
• 
ORR by RECIST Version 1.1 and irRC.  
Secondary Endpoints: 
• 
PFS by RECIST Version 1.1 and irRC. 
• 
OS. 
• 
DOR. 
• 
DCR (confirmed CR, PR, or SD lasting for at least 2 months). 
• 
QoL by PROs. 
• 
Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 
4.03.  
Exploratory Endpoints: 
• 
Tumor molecular profiles and correlations with subject outcomes. 
• 
Therapy-induced changes in immune responses and correlations with subject outcomes. 
• 
Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
10 
Enrollment (planned): 
In the phase 1b portion of the study, 6 to 24 subjects will be enrolled. In the phase 2 portion of the 
study, 23 subjects will be enrolled in the first stage of Simon’s two-stage optimal design.  If the study 
proceeds to the second stage of Simon’s two-stage optimal design, an additional 33 subjects will be 
enrolled in the second stage, for a total of 56 subjects in the phase 2 portion of the study.  The 
maximum total enrollment for the study is 80 subjects. 
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria: 
1. Age ≥ 18 years old. 
2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or 
Independent Ethics Committee (IEC) guidelines. 
3. Histologically-confirmed pancreatic cancer with progression on or after SoC therapy. 
4. ECOG performance status of 0 to 2. 
5. Have at least 1 measurable lesion of ≥ 1.5 cm. 
6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen 
following the conclusion of the most recent anticancer treatment and be willing to release the 
specimen for prospective and exploratory tumor molecular profiling. If an historic specimen 
is not available, the subject must be willing to undergo a biopsy during the screening period, 
if considered safe by the Investigator. If safety concerns preclude collection of a biopsy 
during the screening period, a tumor biopsy specimen collected prior to the conclusion of the 
most recent anticancer treatment may be used. 
7. Must be willing to provide blood samples prior to the start of treatment on this study for 
prospective tumor molecular profiling and exploratory analyses. 
8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for 
exploratory analyses, if considered safe by the Investigator. 
9. Ability to attend required study visits and return for adequate follow-up, as required by this 
protocol. 
10. Agreement to practice effective contraception for female subjects of child-bearing potential 
and non-sterile males.  Female subjects of child-bearing potential must agree to use effective 
contraception for up to 1 year after completion of therapy, and non-sterile male subjects must 
agree to use a condom for up to 4 months after treatment. Effective contraception includes 
surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, 
condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence. 
Exclusion Criteria: 
1. History of persistent grade 2 or higher (CTCAE Version 4.03) hematological toxicity 
resulting from previous therapy. 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
11 
 
2. Within 5 years prior to first dose of study treatment, any evidence of other active 
malignancies or brain metastasis except controlled basal cell carcinoma; prior history of in 
situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under 
active systemic treatment (except hormonal therapy) and with undetectable prostate-specific 
antigen (PSA) (< 0.2 ng/mL); bulky (≥ 1.5 cm) disease with metastasis in the central hilar 
area of the chest and involving the pulmonary vasculature.  
3. Serious uncontrolled concomitant disease that would contraindicate the use of the 
investigational drug used in this study or that would put the subject at high risk for treatment-
related complications. 
4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's 
disease, autoimmune disease associated with lymphoma).   
5. History of organ transplant requiring immunosuppression.   
6. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).   
7. Requires whole blood transfusion to meet eligibility criteria. 
8. Inadequate organ function, evidenced by the following laboratory results: 
a. White blood cell (WBC) count < 3,500 cells/mm3  
b. Absolute neutrophil count < 1,500 cells/mm3. 
c. Platelet count < 100,000 cells/mm3. 
d. Hemoglobin < 9 g/dL. 
e. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has 
documented Gilbert’s syndrome). 
f. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) 
> 2.5 × ULN (> 5 × ULN in subjects with liver metastases). 
g. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, 
or >10 × ULN in subjects with bone metastases). 
h. Serum creatinine > 2.0 mg/dL or 177 μmol/L. 
9. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or 
clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or 
myocardial infarction within 6 months prior to first study medication; unstable angina; 
congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac 
arrhythmia requiring medication. 
10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring 
continuous oxygen therapy. 
11. Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus 
(HBV), or hepatitis C virus (HCV). 
12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids 
(dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled 
steroids.  Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in 
subjects who have known contrast allergies is allowed. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
12 
13. Known hypersensitivity to any component of the study medication(s). 
14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug 
reaction with any of the study medications. 
15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including 
ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, 
ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 
inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, 
and St John's Wort) within 14 days before study day 1. 
16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 
inducer (rifampin) within 14 days before study day 1. 
17. Participation in an investigational drug study or history of receiving any investigational 
treatment within 14 days prior to screening for this study, except for testosterone-lowering 
therapy in men with prostate cancer. 
18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the 
protocol. 
19. Concurrent participation in any interventional clinical trial. 
20. Pregnant and nursing women. 
Products, Dosage, and Mode of Administration: 
Investigational Products 
Dosage 
Mode of Administration 
ALT-803 
10 µg/kg  
SC 
ETBX-011 
5 × 1011 VP/dose  
SC 
GI-4000 
40 YU/dose 
SC 
haNKTM for Infusion 
2 × 109 cells/dose  
IV 
Approved Products 
Dosage 
Mode of Administration 
Avelumab 
10 mg/kg 
IV 
Bevacizumab 
5 mg/kg 
IV 
Capecitabine 
650 mg/m2  
PO BID 
Cyclophosphamide  
50 mg 
PO BID 
5-FU 
400 mg/m2  
16-hour continuous IV infusion 
Leucovorin  
20 mg/m2  
IV bolus 
Nab-paclitaxel  
125 mg  
IV 
Omega-3-acid ethyl esters 
5 g 
PO 
Oxaliplatin 
40 mg/m2 
IV 
SBRT 
8 Gy maximum (exact dose to 
be determined by the radiation 
oncologist) 
External beam radiation 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
13 
Duration of Treatment: 
• 
Induction phase: 8 weeks (minimum) to 1 year (maximum). 
• 
Maintenance phase: Up to 1 year. 
Subjects will be treated for up to 2 years (up to 1 year in each treatment phase) or until they 
experience progressive disease, unacceptable toxicity (not corrected with dose reduction), withdraw 
consent, or if the Investigator feels it is no longer in their best interest to continue treatment. 
Duration of Follow-up:  
Subjects who discontinue study treatment should remain in the study and continue to be followed 
every 90 days (± 14 days) for: 
• 
Resolution of any SAEs attributed to treatment (see Section 7) 
• 
CT, MRI, or PET-CT scan assessment (see Section 6.1.2) 
• 
Vital status: subjects will be followed until either death or for a minimum of 18 months 
past administration of the first dose of chemotherapy to the last subject enrolled in the 
study, whichever comes first. 
Subjects may continue to be followed by the investigational physician or a third party by phone or 
review of medical records approximately every 90 days until withdrawal of consent, lost to follow-up, 
or death (by any cause). Additional information from a subject’s medical records relevant to this 
study may be provided to NantKwest as needed to understand the safety and efficacy of the regimen 
tested in this protocol. 
Reference Therapy, Dosage, and Mode of Administration:  
Not applicable. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
14 
Evaluation of Endpoints: 
Safety:  
Safety endpoints include assessments of treatment-emergent AEs, SAEs, and clinically significant 
changes in safety laboratory tests, physical examinations, ECGs, and vital signs.  All subjects will be 
evaluable for toxicity from the time of their first study treatment.  Toxicities will be graded using the 
NCI CTCAE Version 4.03. 
Efficacy: 
ORR and PFS will be assessed by CT, MRI, or PET-CT of target and non-target lesions every 
8 weeks during the induction phase and every 12 weeks during the maintenance phase and will be 
evaluated in accordance with RECIST Version 1.1 and irRC.  OS, DOR, and DCR will also be 
assessed. 
An assessment of QoL will be conducted via PROs using the Functional Assessment of Cancer 
Therapy-Hepatobiliary Cancer (FACT-Hep) instrument on study day 1, every 28 days thereafter, and 
at the end-of-treatment (EOT) visit. 
Exploratory Analysis: 
Tumor Molecular Profiling: Genomic sequencing of tumor cells from tissue relative to non-tumor 
cells from whole blood will be conducted to identify tumor-specific genomic variances that may 
contribute to disease progression and/or response to treatment RNA sequencing will be conducted to 
provide expression data and give relevance to DNA mutations. Quantitative proteomics analysis will 
be conducted to determine the absolute amounts of specific proteins, to confirm expression of genes 
that are correlative of disease progression and/or response, and to determine the cutoff values for 
response. 
Immunologic Analysis: Immune responses to the NANT pancreatic cancer regimen will be evaluated 
by flow cytometry and enzyme-linked immunospot (ELISpot) assays. Correlations between therapy-
induced immune changes and subject outcomes will be assessed. 
ctDNA/ctRNA Analysis: ctDNA and ctRNA will be extracted from plasma obtained from whole 
blood. Expression levels of specific tumor- and immune-related analytes will be assessed by 
quantitative real-time polymerase chain reaction (qPCR) and possibly other methods (eg, DNA/RNA 
sequencing) and analyzed for correlations with subject outcomes. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
15 
Statistical Methods: 
This phase 1b/2 study will examine the overall safety profile and preliminary efficacy of metronomic 
combination therapy in subjects with pancreatic cancer whose tumors have progressed on or after SoC 
treatment. 
Safety results will be presented separately for the induction and maintenance phases of treatment as 
well as overall for the entire treatment regimen. Efficacy results will be summarized for the overall 
treatment regimen. 
Overall safety will be assessed by descriptive analyses using tabulated frequencies of AEs by grade 
using CTCAE version 4.03 in terms of treatment-emergent AEs, SAEs, and clinically significant 
changes in safety laboratory tests, physical examinations, ECGs, and vital signs. 
ORR will be evaluated in accordance with RECIST Version 1.1 and irRC.  The percentage of subjects 
(and 95% confidence interval [CI]) who achieve a confirmed response will be summarized.  DCR will 
be evaluated similar to ORR.  PFS, OS, and DOR will be analyzed using Kaplan-Meier methods.  
Descriptive statistics of PROs will be presented. 
Correlations of tumor molecular profiles, therapy-induced changes in immune responses, and 
molecular changes in ctDNA and ctRNA with subject outcomes will be explored. 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
16 
Figure 1: 
Study Treatment Schema 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
17 
Figure 2: 
Induction Phase Treatment Schema 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
18 
Figure 3: 
Maintenance Phase Treatment Schema 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
124 
Table 19: 
Schedule of Events for Induction Phase of Study 
 
Screening 
Induction Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
-28 to -1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
General Assessments 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusiond 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical historye 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm availability of 
FFPE tumor samplef 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medications 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
Physical exam: heightg, 
weight 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
Vital signsh 
X 
X 
 
X 
 
X 
 
 
X 
X 
X 
X 
X 
 
 
X 
X 
ECOG performance status 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
12-lead ECGi 
X 
X 
Every 4 weeks 
X 
 
Confirm contraceptive 
measures 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACT-Hep Questionnaire 
X 
X 
Every 4 weeks 
X 
 
Adverse event collection 
 
X 
 
X 
 
X 
 
 
X 
X 
X 
X 
X 
 
 
X 
X 
Laboratory Assessments 
Chemistry panelj 
X 
Xk 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
CA19-9 
X 
X
k 
Every 4 weeks 
X 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
125 
 
Screening 
Induction Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
-28 to -1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
Hematologyl 
X 
X
k 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Urinalysis 
X 
X
k 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Pregnancy testm 
X 
X
k 
Every 4 weeks 
X 
 
Serum virology (HIV, 
HBV, HCV)n 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine RAS mutational 
statuso 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect whole blood for 
tumor molecular profilingp 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect whole blood for 
immunology analysisq 
X 
Every 4 weeks during routine blood draws 
X 
 
Collect whole blood for 
ctDNA/ctRNA analysisq 
X 
Every 4 weeks during routine blood draws 
X 
 
Collect historic tumor 
biopsy specimen for tumor 
molecular profilingr 
X 
 
 
 
Tumor biopsyr 
X 
At the end of the initial induction phase (8 weeks after the start of treatment) 
 
 
Additional tumor biopsy 
May be collected at any time point, as clinically indicated at the Investigator’s discretion. 
Tumor Imaging and Assessments 
CT, MRI, or PET-CTs
 
X 
Every 8 weeks 
X 
 
a Subjects will remain in the induction phase of the study for up to 1 year. Treatment will continue in the induction phase until the subject experiences PD or 
unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue 
treatment. Those who have a CR in the induction phase will enter the maintenance phase of the study.  
b End-of-treatment visit must be performed 30 (±5 days) after the last study treatment. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
126 
c Additional assessments performed during an unscheduled visit are at the discretion of the Investigator or treating physician and must be recorded in the 
subject’s source documents and on the Unscheduled Visit eCRF. 
d Inclusion/exclusion criteria will also be evaluated at enrollment. 
e Medical history will also be evaluated at enrollment. 
f Subject’s FFPE tumor tissue sample must be obtained following the conclusion of the most recent anticancer treatment and prior to first study treatment. If not 
available, a fresh tumor biopsy must be performed. In the event a fresh biopsy needs to be scheduled, the site may consent the subject and schedule the 
screening visit assessments to be performed such that all assessments fall within 28 days prior to the first dose of any study drug. If safety concerns preclude 
collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be 
used. 
g Height required at screening visit only. 
h Vital signs of temperature, heart rate, blood pressure, and respiratory rate will be assessed at every visit. Vitals signs are to be obtained after the subject has 
been in a seated resting position for at least 5 minutes. For visits where a subject is receiving an infusion of any study compounds, vital signs will be recorded 
at 15 minutes and 30 minutes after the start of the infusion and, except for 5-FU, at 30-minute intervals thereafter through the post-infusion hydration period. 
i 12-lead ECG to be performed in triplicate at screening. 
j Chemistry panel to include laboratory assessments noted in Table 18.  
k Day 1 assessments can be skipped if the screening assessment was performed within 1 week prior to the start of treatment. 
l Hematology to include CBC with differential (5 part) and platelets with hemoglobin and hematocrit. 
m Serum pregnancy test at screening; urine dipstick pregnancy test for all other visits (for females of child-bearing potential). 
n Virology tests include HIV (as determined by ELISA and confirmed by western blot) and HBV/HCV (as determined by HBsAg and hepatitis C serology). 
o Assessment of RAS mutational status to determine whether GI-4000 will be administered to the subject, as described in Section 3.1.1. 
p Whole blood for tumor molecular profiling will be collected during the screening period for subjects who have been enrolled in the study. 
q Whole blood for immunology and ctDNA/ctRNA analyses will be collected during the screening period for subjects who have been enrolled in the study, every 
4 weeks in the induction phase during routine blood draws, and at the EOT visit. 
r Historic tumor biopsy specimen for tumor molecular profiling will be collected only for subjects enrolled in the study. If an historic specimen is not available, a 
fresh tumor biopsy must be performed, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a 
tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used. In the event a fresh biopsy needs to be scheduled, 
the site may consent the subject and schedule the screening visit assessments to be performed such that all assessments fall within 28 days prior to the first dose 
of any study medications. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the 
conclusion of the most recent anticancer treatment may be used. A tumor biopsy is also required at the end of the initial induction phase (8 weeks after the start 
of treatment), if considered safe by the Investigator 
s Tumor imaging by CT scan, MRI, or PET-CT will be performed at screening and every 8 weeks thereafter in the induction phase. Evaluations may include CT, 
MRI, or PET-CT scans of the chest, abdomen, pelvis (optional unless known pelvic disease is present at screening), and brain (only as clinically warranted 
based on symptoms/findings). All screening tumor imaging assessments should be performed based on the subject's qualifying scan obtained within 28 days 
prior to the start of treatment. RECIST and irRC documentation to be completed at each assessment period. The same mode of imaging is required to be carried 
through each subject’s respective treatment period. 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
127 
Table 20: 
Schedule of Events for Maintenance Phase of Study 
 
Maintenance Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
Concomitant medications 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Physical exam, weight 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Vital signsd 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X 
ECOG performance status 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
12-lead ECG 
X 
Every 4 weeks 
X 
 
Confirm contraceptive 
measures 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse event collection 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X 
FACT-Hep 
X 
Every 4 weeks 
X 
 
Laboratory Assessments 
Chemistry panele 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
CA19-9  
X 
Every 4 weeks 
X 
 
Hematologyf 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Urinalysis 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Pregnancy testg 
X 
Every 4 weeks 
X 
 
Collect whole blood for 
immunology analysish 
X 
Every 8 weeks during routine blood draws 
X 
 
Collect whole blood for 
ctDNA/ctRNA analysish 
X 
Every 8 weeks during routine blood draws 
X 
 
Additional tumor biopsy 
May be collected at any time point, as clinically indicated at the Investigator’s discretion 
 CT, MRI, or PET-CTi 
X 
Every 12 weeks 
X 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 
 
Confidential and Proprietary 
128 
a Subjects will remain in the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD 
or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to 
continue treatment. 
b EOT visit must be performed 30 (±5 days) after the last study treatment. 
c Additional assessments performed during an unscheduled visit are at the discretion of the PI or treating physician and must be recorded in the subject’s source 
documents and on the Unscheduled Visit eCRF. 
d Vital signs of temperature, heart rate, blood pressure, and respiratory rate will be assessed at every visit.  Vitals signs are to be obtained after the subject has 
been in a seated resting position for at least 5 minutes. For visits where a subject is receiving an infusion of any study compounds, vital signs will be recorded 
at 15 minutes and 30 minutes after the start of the infusion and, except for 5-FU, at 30-minute intervals thereafter through the post-infusion hydration period. 
e Chemistry panel to include laboratory assessments noted in Table 18. 
f Hematology to include CBC with differential (5 part) and platelets with hemoglobin and hematocrit. 
g Urine dipstick pregnancy test for females of child-bearing potential. 
h Blood collection for exploratory immunology and ctDNA/ctRNA analyses will be performed every 8 weeks in the maintenance phase during routine blood 
draws, and at the end-of-treatment visit.  
i Tumor imaging by CT scan, MRI, or PET-CT will be performed every 12 weeks in the maintenance phase. Evaluations may include CT, MRI, or PET-CT 
scans of the chest, abdomen, pelvis (optional unless known pelvic disease is present at screening), and brain (only as clinically warranted based on 
symptoms/findings). RECIST and irRC documentation to be completed at each assessment period. The same mode of imaging is required to be carried through 
each subject’s respective treatment period. 

NANT Pancreatic Cancer Vaccine 
Clinical Trial Protocol: QUILT-3.060 
APPENDIX 1. 
SPONSOR SIGNATURE 
NantKwest, Inc. 
Study Title: 
NANT Pancreatic Cancer Vaccine: Combination immunotherapy 
with high-affinity natural killer (haNK) cell therapy in subjects 
with pancreatic cancer who have progressed on or after standard-
of-care therapy. 
Study Number: 
QUILT-3.060 
Version Number: 
1 
Final Date: 
15 September 201 7 
This clinical trial protocol was subject to critical review and has been approved by NantKwest. 
The following personnel contributed to writing and/or approving this protocol: 
Date: 9- /rf-tt-
H.Lee,MD 
Senior Vice President Adult Medical Affairs, NantKwest Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Email: John.Lee@Nantkwest.com 
Cell Phone: + 1-605-610-6391 
Confidential and Proprietary 
163 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
1 
TITLE PAGE 
NANT PANCREATIC CANCER VACCINE: 
COMBINATION IMMUNOTHERAPY WITH 
HIGH-AFFINITY NATURAL KILLER (haNK) CELL 
THERAPY IN SUBJECTS WITH PANCREATIC 
CANCER WHO HAVE PROGRESSED ON OR AFTER 
STANDARD-OF-CARE THERAPY 
 
Study Number: 
QUILT-3.060 
IND Sponsor: 
NantKwest, Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Sponsor Contact:  
(For medical questions/emergencies) 
John H. Lee, MD 
Senior Vice President Adult Medical Affairs, 
NantKwest Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Email: John.Lee@Nantkwest.com 
Cell Phone: +1-605-610-6391 
 
Protocol Version 
Date 
Version 1 
15 September 2017 
Version 2 
15 February 2018 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
2 
STATEMENT OF COMPLIANCE 
This trial will be conducted in accordance with Good Clinical Practice (GCP) as described in the 
International Conference on Harmonization Guideline E6 (ICH E6) and in accordance with 
United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312) and the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
Institutional Review Board (IRB) prior to commencement.  The Principal Investigator will assure 
that no deviation from, or changes to the protocol will take place without prior agreement from 
NantKwest and documented approval from the IRB, except where necessary to eliminate an 
immediate hazard(s) to the trial participants.  
I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.  
 
Principal Investigator:  
 
Signed: _____________________________________ Date: ______________ 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
3 
PROTOCOL SYNOPSIS 
Name of Sponsor/Company: 
NantKwest, Inc. 
Name of Investigational Products:  
1. ALT-803 (recombinant human super agonist interleukin-15 (IL-15) complex [also known as 
IL 15N72D:IL-15RαSu/IgG1 Fc complex]) 
2. ETBX-011 (adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA [carcinoembryonic antigen]) 
3. GI-4000 (RAS yeast vaccine) 
4. haNK™, NK-92 [CD16.158V, ER IL-2], Suspension for Infusion (haNK™ for Infusion) 
Name of Approved Products: 
5. Avelumab (BAVENCIO® injection, for IV use) 
6. Bevacizumab (AVASTIN® solution for IV infusion) 
7. Capecitabine (XELODA® tablets, for oral use) 
8. Cyclophosphamide (Cyclophosphamide Capsules, for oral use; or Cyclophosphamide 
Tablets, USP) 
9. 5-Fluorouracil (5-FU; Fluorouracil Injection, for IV use only) 
10. Leucovorin (LEUCOVORIN Calcium for Injection, for IV or intramuscular [IM] use) 
11. Nab-paclitaxel (ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles 
for injectable suspension] [albumin-bound]) 
12. Oxaliplatin (ELOXATIN® injection for IV use) 
13. Stereotactic Body Radiation Therapy (SBRT) 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
4 
Name of Active Ingredients 
Investigational Products: 
1. ALT-803, recombinant human super agonist interleukin-15 (IL-15) complex (also known as 
IL 15N72D:IL-15RαSu/IgG1 Fc complex) 
2. Ad5 [E1-, E2b-]-CEA 
3. GI-4014 expressing mutations in RAS at codon 12 (G12V), and codon 61 (Q61R and Q61L); 
GI-4015 expressing mutations in RAS at codon 12 (G12C), and codon 61 (Q61R and Q61L); 
GI-4016 expressing mutations in RAS at codon 12 (G12D) and codon 61 (Q61R and Q61L); 
and GI-4020 expressing mutations in RAS at codon 12 (G12R) and codon 61 (Q61L and 
Q61H) 
4. NK-92 [CD16.158V, ER IL2] cells 
Approved Products: 
5. Avelumab 
6. Bevacizumab 
7. Capecitabine 
8. Cyclophosphamide (anhydrous) 
9. Fluorouracil, USP 
10. Leucovorin (calcium salt) 
11. Paclitaxel, USP 
12. Oxaliplatin, USP 
13. Radiation 
Title of Study:  
NANT Pancreatic Cancer Vaccine: combination immunotherapy with high-affinity natural killer 
(haNK) in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy. 
Study Number: 
QUILT-3.060 
Study Phase: 
Phase 1b/2 (Simon’s two-stage optimal design). 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
5 
Study Objectives: 
Phase 1b 
• 
The primary objective is to evaluate the overall safety profile of the NANT pancreatic 
cancer regimen in subjects with pancreatic cancer who have progressed after standard-of-
care (SoC) therapy. 
• 
Secondary objectives are to obtain preliminary estimates of efficacy by objective 
response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of 
response (DOR), disease control rate (DCR), and quality of life (QoL) by patient-reported 
outcomes (PROs). 
• 
Exploratory objectives include the assessment of tumor molecular profiles (genomics, 
transcriptomics, and proteomics), therapy-induced changes in immune responses, and 
molecular changes in circulating tumor DNA (ctDNA) and RNA (ctRNA); and their 
correlations with subject outcomes. 
Phase 2  
• 
The primary objective is to determine the efficacy of the NANT pancreatic cancer 
regimen as assessed by ORR. 
• 
Secondary objectives are to obtain additional measures of safety and efficacy (PFS, OS, 
DOR, DCR, and QoL by PROs). 
• 
Exploratory objectives include the assessment of tumor molecular profiles, therapy-
induced changes in immune responses, and molecular changes in ctDNA and ctRNA; and 
their correlations with subject outcomes. 
Study Design: 
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in 
subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy. Phase 2 
will be based on Simon’s two-stage optimal design. 
Preliminary assessment of the safety of the treatment regimen will occur by an Independent Data 
Safety Monitoring Committee (IDMC) and the NantKwest Safety Review Committee (SRC). 
Enrollment into the phase 1b portion will continue if data from the initial 3 subjects suggest that the 
combination therapy is tolerable. 
Treatment will be administered in two phases, an induction and a maintenance phase, as described 
below.  Subjects will continue induction treatment for up to 1 year. Treatment in the study will be 
discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not 
corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the 
subject’s best interest to continue treatment. Those who have a complete response (CR) in the 
induction phase will enter the maintenance phase of the study. Subjects may remain on the 
maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase 
until the subject experiences PD or unacceptable toxicity (not corrected with dose reduction), 
withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue 
treatment. The maximum time on study treatment, including both the induction and maintenance 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
6 
phases, is 2 years. 
Exploratory tumor molecular profiling will be conducted on samples collected prior to treatment on 
this study, 8 weeks after the start of treatment, and during potential prolonged induction and 
maintenance phases (depending on response), as described in Section 6.4.1. Separate blood tubes will 
be collected every 4 weeks in the induction phase and every 8 weeks in the maintenance phase during 
routine blood draws for exploratory immunology and ctDNA/ctRNA analyses, as described in 
Section 6.4.2 and Section 6.4.3, respectively. 
Tumors will be assessed at screening, and tumor response will be assessed every 8 weeks during the 
induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT), 
magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT of target and non-
target lesions in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 
Version 1.1 and immune-related response criteria (irRC). 
Prospective Tumor Molecular Profiling 
Prospective tumor molecular profiling will be conducted to inform RAS mutational status and will be 
used to determine whether GI-4000 will be administered. All subjects will receive all other agents 
regardless of their tumor molecular profile. 
Prospective tumor molecular profiling will be performed on FFPE tumor tissue and whole blood 
(subject-matched normal comparator against the tumor tissue) collected at screening. More 
information on the collection of tumor tissue and whole blood is described in Section 6.4.1.2 and is 
similar to the collection of samples for the exploratory tumor molecular profiling. 
Subjects will receive GI-4000 if their tumor is positive for specific RAS mutations, as determined by 
whole genome sequencing. As described in Section 1.6.8.1, GI-4000 is 4 separate products from the 
GI-4000 series (GI-4014, GI-4015, GI- 4016, and GI-4020); each of these expresses a combination of 
mutated RAS oncoproteins. The specific RAS mutation will determine which GI-4000 product will be 
used for treatment (GI-4014 for G12V, GI-4015 for G12C, GI-4016 for G12D, GI-4020 for G12R or 
Q61H, and GI-4014, GI-4015, or GI-4016 for Q61L or Q61R).  
Induction Phase: 
Treatment in the induction phase will consist of repeated 2-week cycles for a maximum treatment 
period of 1 year, as follows: 
Day 1 every 2 weeks:  
• 
Bevacizumab (5 mg/kg IV) 
Days 1–5 and 8–12, every 2 weeks:  
• 
Cyclophosphamide (50 mg by mouth [PO] twice a day [BID]) 
Days 1, 3, 5, 8, 10 and 12, every 2 weeks: 
• 
5-FU (400 mg/m2 continuous IV infusion over 16–24 hours)   
• 
Leucovorin (20 mg/m2 IV bolus) 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
7 
Day 1 and 8, every 2 weeks:  
• 
Nab-paclitaxel (125 mg IV) 
• 
Oxaliplatin (40 mg/m2 IV) 
Day 5, 19, 33 (every 2 weeks for 3 doses then every 8 weeks thereafter):   
• 
ETBX-011 (5 × 1011 virus particles [VP]/dose subcutaneously [SC]) 
• 
GI-4000 (40 yeast units [YU]/dose SC), 2 hours after administration of the Ad5-based 
vaccine 
Prospective tumor molecular profiling will determine whether GI-4000 will be 
administered, as described above. 
Day 8, every 2 weeks: 
• 
Avelumab (10 mg/kg IV over 1 hour) 
Day 8, 22, 36, 50 (every 2 weeks for 4 doses): 
• 
SBRT (not to exceed 8 Gy, exact dose to be determined by the radiation oncologist) 
Day 9, every 2 weeks:  
• 
ALT-803 (10 μg/kg SC at least 30 minutes prior to haNK infusion) 
Day 9 and 11, every 2 weeks:  
• 
haNK (2 x 109 cells/dose IV) 
Maintenance Phase: 
The duration of the maintenance phase will be up to 1 year following completion of the last treatment 
in the induction phase, as follows: 
Day 1, every 2 weeks:  
• 
Avelumab (10 mg/kg IV over 1 hour)  
• 
Bevacizumab (5 mg/kg IV) 
• 
Nab-paclitaxel (125 mg IV) 
Days 1–5 and 8–12, every 2 weeks: 
• 
Capecitabine (650 mg/m2 PO BID) 
• 
Cyclophosphamide (50 mg PO BID) 
Day 2, every 2 weeks:  
• 
ALT-803 (10 µg/kg SC, at least 30 minutes prior to haNK infusion) 
• 
haNK (2 x 109 cells/dose IV)  
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
8 
Day 5, every 8 weeks thereafter: 
• 
ETBX-011 (5 × 1011 VP/dose SC) 
• 
GI-4000 (40 YU/dose SC), 2 hours after administration of the Ad5-based vaccine 
Prospective molecular profiling will determine whether GI-4000 will be administered, as 
described above. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
9 
Phase 1b 
Primary Endpoint: 
• 
Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded 
using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03. 
Secondary Endpoints: 
• 
ORR by RECIST Version 1.1 and irRC. 
• 
PFS by RECIST Version 1.1 and irRC. 
• 
OS. 
• 
DOR. 
• 
DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months). 
• 
QoL by PROs. 
Exploratory Endpoints: 
• 
Tumor molecular profiles and correlations with subject outcomes. 
• 
Therapy-induced changes in immune responses and correlations with subject outcomes. 
• 
Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. 
Phase 2 
Primary Endpoint: 
• 
ORR by RECIST Version 1.1 and irRC.  
Secondary Endpoints: 
• 
PFS by RECIST Version 1.1 and irRC. 
• 
OS. 
• 
DOR. 
• 
DCR (confirmed CR, PR, or SD lasting for at least 2 months). 
• 
QoL by PROs. 
• 
Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 
4.03.  
Exploratory Endpoints: 
• 
Tumor molecular profiles and correlations with subject outcomes. 
• 
Therapy-induced changes in immune responses and correlations with subject outcomes. 
• 
Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
10 
Enrollment (planned): 
In the phase 1b portion of the study, 6 to 24 subjects will be enrolled. In the phase 2 portion of the 
study, 23 subjects will be enrolled in the first stage of Simon’s two-stage optimal design.  If the study 
proceeds to the second stage of Simon’s two-stage optimal design, an additional 33 subjects will be 
enrolled in the second stage, for a total of 56 subjects in the phase 2 portion of the study.  The 
maximum total enrollment for the study is 80 subjects. 
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria: 
1. Age ≥ 18 years old. 
2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or 
Independent Ethics Committee (IEC) guidelines. 
3. Histologically-confirmed pancreatic cancer with progression on or after SoC therapy. 
4. ECOG performance status of 0 to 2. 
5. Have at least 1 measurable lesion of ≥ 1.5 cm. 
6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen 
following the conclusion of the most recent anticancer treatment and be willing to release the 
specimen for prospective and exploratory tumor molecular profiling. If an historic specimen 
is not available, the subject must be willing to undergo a biopsy during the screening period, 
if considered safe by the Investigator. If safety concerns preclude collection of a biopsy 
during the screening period, a tumor biopsy specimen collected prior to the conclusion of the 
most recent anticancer treatment may be used. 
7. Must be willing to provide blood samples prior to the start of treatment on this study for 
prospective tumor molecular profiling and exploratory analyses. 
8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for 
exploratory analyses, if considered safe by the Investigator. 
9. Ability to attend required study visits and return for adequate follow-up, as required by this 
protocol. 
10. Agreement to practice effective contraception for female subjects of child-bearing potential 
and non-sterile males.  Female subjects of child-bearing potential must agree to use effective 
contraception for up to 1 year after completion of therapy, and non-sterile male subjects must 
agree to use a condom for up to 4 months after treatment. Effective contraception includes 
surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, 
condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence. 
Exclusion Criteria: 
1. History of persistent grade 2 or higher (CTCAE Version 4.03) hematological toxicity 
resulting from previous therapy. 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
11 
 
2. Within 5 years prior to first dose of study treatment, any evidence of other active 
malignancies or brain metastasis except controlled basal cell carcinoma; prior history of in 
situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under 
active systemic treatment (except hormonal therapy) and with undetectable prostate-specific 
antigen (PSA) (< 0.2 ng/mL); bulky (≥ 1.5 cm) disease with metastasis in the central hilar 
area of the chest and involving the pulmonary vasculature.  
3. Serious uncontrolled concomitant disease that would contraindicate the use of the 
investigational drug used in this study or that would put the subject at high risk for treatment-
related complications. 
4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's 
disease, autoimmune disease associated with lymphoma).   
5. History of organ transplant requiring immunosuppression.   
6. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).   
7. Requires whole blood transfusion to meet eligibility criteria. 
8. Inadequate organ function, evidenced by the following laboratory results: 
a. White blood cell (WBC) count < 3,500 cells/mm3  
b. Absolute neutrophil count < 1,500 cells/mm3. 
c. Platelet count < 100,000 cells/mm3. 
d. Hemoglobin < 9 g/dL. 
e. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has 
documented Gilbert’s syndrome). 
f. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) 
> 2.5 × ULN (> 5 × ULN in subjects with liver metastases). 
g. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, 
or >10 × ULN in subjects with bone metastases). 
h. Serum creatinine > 2.0 mg/dL or 177 μmol/L. 
9. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or 
clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or 
myocardial infarction within 6 months prior to first study medication; unstable angina; 
congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac 
arrhythmia requiring medication. 
10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring 
continuous oxygen therapy. 
11. Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus 
(HBV), or hepatitis C virus (HCV). 
12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids 
(dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled 
steroids.  Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in 
subjects who have known contrast allergies is allowed. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
12 
13. Known hypersensitivity to any component of the study medication(s). 
14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug 
reaction with any of the study medications. 
15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including 
ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, 
ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 
inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, 
and St John's Wort) within 14 days before study day 1. 
16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 
inducer (rifampin) within 14 days before study day 1. 
17. Participation in an investigational drug study or history of receiving any investigational 
treatment within 14 days prior to screening for this study, except for testosterone-lowering 
therapy in men with prostate cancer. 
18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the 
protocol. 
19. Concurrent participation in any interventional clinical trial. 
20. Pregnant and nursing women. 
Products, Dosage, and Mode of Administration: 
Investigational Products 
Dosage 
Mode of Administration 
ALT-803 
10 µg/kg  
SC 
ETBX-011 
5 × 1011 VP/dose  
SC 
GI-4000 
40 YU/dose 
SC 
haNKTM for Infusion 
2 × 109 cells/dose  
IV 
Approved Products 
Dosage 
Mode of Administration 
Avelumab 
10 mg/kg 
IV 
Bevacizumab 
5 mg/kg 
IV 
Capecitabine 
650 mg/m2 PO 
BID 
Cyclophosphamide  
50 mg PO 
BID 
5-FU 
400 mg/m2  
16–24 hour continuous IV 
infusion 
Leucovorin  
20 mg/m2  
IV bolus 
Nab-paclitaxel  
125 mg  
IV 
Oxaliplatin 
40 mg/m2 
IV 
SBRT 
8 Gy maximum (exact dose to 
be determined by the radiation 
oncologist) 
External beam radiation 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
13 
Duration of Treatment: 
• 
Induction phase: 8 weeks (minimum) to 1 year (maximum). 
• 
Maintenance phase: Up to 1 year. 
Subjects will be treated for up to 2 years (up to 1 year in each treatment phase) or until they 
experience progressive disease, unacceptable toxicity (not corrected with dose reduction), withdraw 
consent, or if the Investigator feels it is no longer in their best interest to continue treatment. 
Duration of Follow-up:  
Subjects who discontinue study treatment should remain in the study and continue to be followed 
every 90 days (± 14 days) for: 
• 
Resolution of any SAEs attributed to treatment (see Section 7) 
• 
CT, MRI, or PET-CT scan assessment (see Section 6.1.2) 
• 
Vital status: subjects will be followed until either death or for a minimum of 18 months 
past administration of the first dose of chemotherapy to the last subject enrolled in the 
study, whichever comes first. 
Subjects may continue to be followed by the investigational physician or a third party by phone or 
review of medical records approximately every 90 days until withdrawal of consent, lost to follow-up, 
or death (by any cause). Additional information from a subject’s medical records relevant to this 
study may be provided to NantKwest as needed to understand the safety and efficacy of the regimen 
tested in this protocol. 
Reference Therapy, Dosage, and Mode of Administration:  
Not applicable. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
14 
Evaluation of Endpoints: 
Safety:  
Safety endpoints include assessments of treatment-emergent AEs, SAEs, and clinically significant 
changes in safety laboratory tests, physical examinations, ECGs, and vital signs.  All subjects will be 
evaluable for toxicity from the time of their first study treatment.  Toxicities will be graded using the 
NCI CTCAE Version 4.03. 
Efficacy: 
ORR and PFS will be assessed by CT, MRI, or PET-CT of target and non-target lesions every 
8 weeks during the induction phase and every 12 weeks during the maintenance phase and will be 
evaluated in accordance with RECIST Version 1.1 and irRC.  OS, DOR, and DCR will also be 
assessed. 
An assessment of QoL will be conducted via PROs using the Functional Assessment of Cancer 
Therapy-Hepatobiliary Cancer (FACT-Hep) instrument on study day 1, every 28 days thereafter, and 
at the end-of-treatment (EOT) visit. 
Exploratory Analysis: 
Tumor Molecular Profiling: Genomic sequencing of tumor cells from tissue relative to non-tumor 
cells from whole blood will be conducted to identify tumor-specific genomic variances that may 
contribute to disease progression and/or response to treatment RNA sequencing will be conducted to 
provide expression data and give relevance to DNA mutations. Quantitative proteomics analysis will 
be conducted to determine the absolute amounts of specific proteins, to confirm expression of genes 
that are correlative of disease progression and/or response, and to determine the cutoff values for 
response. 
Immunologic Analysis: Immune responses will be evaluated by standard immune assays. 
Correlations between therapy-induced immune changes and subject outcomes will be assessed. 
ctDNA/ctRNA Analysis: ctDNA and ctRNA will be extracted from plasma obtained from whole 
blood. Expression levels of specific tumor- and immune-related analytes will be assessed by 
quantitative real-time polymerase chain reaction (qPCR) and possibly other methods (eg, DNA/RNA 
sequencing) and analyzed for correlations with subject outcomes. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
15 
Statistical Methods: 
This phase 1b/2 study will examine the overall safety profile and preliminary efficacy of metronomic 
combination therapy in subjects with pancreatic cancer whose tumors have progressed on or after SoC 
treatment. 
Safety results will be presented separately for the induction and maintenance phases of treatment as 
well as overall for the entire treatment regimen. Efficacy results will be summarized for the overall 
treatment regimen. 
Overall safety will be assessed by descriptive analyses using tabulated frequencies of AEs by grade 
using CTCAE version 4.03 in terms of treatment-emergent AEs, SAEs, and clinically significant 
changes in safety laboratory tests, physical examinations, ECGs, and vital signs. 
ORR will be evaluated in accordance with RECIST Version 1.1 and irRC.  The percentage of subjects 
(and 95% confidence interval [CI]) who achieve a confirmed response will be summarized.  DCR will 
be evaluated similar to ORR.  PFS, OS, and DOR will be analyzed using Kaplan-Meier methods.  
Descriptive statistics of PROs will be presented. 
Correlations of tumor molecular profiles, therapy-induced changes in immune responses, and 
molecular changes in ctDNA and ctRNA with subject outcomes will be explored. 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
16 
Figure 1: 
Study Treatment Schema 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
17 
Figure 2: 
Induction Phase Treatment Schema 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
18 
Figure 3: 
Maintenance Phase Treatment Schema 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
122 
Table 19: 
Schedule of Events for Induction Phase of Study 
 
Screening 
Induction Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
-28 to -1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
General Assessments 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusiond 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical historye 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm availability of 
FFPE tumor samplef 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medications 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
Physical exam: heightg, 
weight 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
Vital signsh 
X 
X 
 
X 
 
X 
 
 
X 
X 
X 
X 
X 
 
 
X 
X 
ECOG performance status 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
12-lead ECGi 
X 
X 
Every 4 weeks 
X 
 
Confirm contraceptive 
measures 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACT-Hep Questionnaire 
X 
X 
Every 4 weeks 
X 
 
Adverse event collection 
 
X 
 
X 
 
X 
 
 
X 
X 
X 
X 
X 
 
 
X 
X 
Laboratory Assessments 
Chemistry panelj 
X 
Xk 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
CA19-9 
X 
X
k 
Every 4 weeks 
X 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
123 
 
Screening 
Induction Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
-28 to -1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
Hematologyl 
X 
X
k 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Urinalysis 
X 
X
k 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Pregnancy testm 
X 
X
k 
Every 4 weeks 
X 
 
Serum virology (HIV, 
HBV, HCV)n 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine RAS mutational 
statuso 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect whole blood for 
tumor molecular profilingp 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect whole blood for 
immunology analysisq 
X 
Every 4 weeks during routine blood draws 
X 
 
Collect whole blood for 
ctDNA/ctRNA analysisq 
X 
Every 4 weeks during routine blood draws 
X 
 
Collect historic tumor 
biopsy specimen for tumor 
molecular profilingr 
X 
 
 
 
Tumor biopsyr 
X 
At the end of the initial induction phase (8 weeks after the start of treatment) 
 
 
Additional tumor biopsy 
May be collected at any time point, as clinically indicated at the Investigator’s discretion. 
Tumor Imaging and Assessments 
CT, MRI, or PET-CTs
 
X 
Every 8 weeks 
X 
 
a Subjects will remain in the induction phase of the study for up to 1 year. Treatment will continue in the induction phase until the subject experiences PD or 
unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue 
treatment. Those who have a CR in the induction phase will enter the maintenance phase of the study. Any required blood draws and safety laboratory sample 
collections (including urinalysis) may be performed within a 3-day window of the time indicated. 
b End-of-treatment visit must be performed 30 (±5 days) after the last study treatment. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
124 
c Additional assessments performed during an unscheduled visit are at the discretion of the Investigator or treating physician and must be recorded in the 
subject’s source documents and on the Unscheduled Visit eCRF. 
d Inclusion/exclusion criteria will also be evaluated at enrollment. 
e Medical history will also be evaluated at enrollment. 
f Subject’s FFPE tumor tissue sample must be obtained following the conclusion of the most recent anticancer treatment and prior to first study treatment. If not 
available, a fresh tumor biopsy must be performed. In the event a fresh biopsy needs to be scheduled, the site may consent the subject and schedule the 
screening visit assessments to be performed such that all assessments fall within 28 days prior to the first dose of any study drug. If safety concerns preclude 
collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be 
used. 
g Height required at screening visit only. 
h Vital signs of temperature, heart rate, blood pressure, and respiratory rate will be assessed at every visit. Vital signs are to be obtained after the subject has been 
in a seated resting position for at least 5 minutes and within 30 minutes prior to the start of any infusional study treatment. For visits where a subject is 
receiving an infusion of any study compounds, vital signs will be collected at the following time points in relation to the start of first infusion of the day: prior 
to infusion, 15 minutes post, 30 minutes post, and hourly until the subject is discharged. Temperature will be documented each visit at the first pre-infusion 
assessment of vital signs and subsequently if clinically indicated. 
i 12-lead ECG to be performed in triplicate at screening. 
j Chemistry panel to include laboratory assessments noted in Table 18.  
k Day 1 assessments can be skipped if the screening assessment was performed within 1 week prior to the start of treatment. 
l Hematology to include CBC with differential (5 part) and platelets with hemoglobin and hematocrit. 
m Serum pregnancy test for females of child-bearing potential. 
n Virology tests include HIV (as determined by ELISA and confirmed) and HBV/HCV (as determined by HBsAg and hepatitis C serology). 
o Assessment of RAS mutational status to determine whether GI-4000 will be administered to the subject, as described in Section 3.1.1. 
p Whole blood for tumor molecular profiling will be collected during the screening period for subjects who have been enrolled in the study. 
q Whole blood for immunology and ctDNA/ctRNA analyses will be collected during the screening period for subjects who have been enrolled in the study, every 
4 weeks in the induction phase during routine blood draws, and at the EOT visit. 
r Historic tumor biopsy specimen for tumor molecular profiling will be collected only for subjects enrolled in the study. If an historic specimen is not available, a 
fresh tumor biopsy must be performed, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a 
tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used. In the event a fresh biopsy needs to be scheduled, 
the site may consent the subject and schedule the screening visit assessments to be performed such that all assessments fall within 28 days prior to the first dose 
of any study medications. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the 
conclusion of the most recent anticancer treatment may be used. A tumor biopsy is also required 8 weeks after the start of treatment, if considered safe by the 
Investigator 
s Tumor imaging by CT scan, MRI, or PET-CT will be performed at screening and every 8 weeks thereafter in the induction phase. Evaluations may include CT, 
MRI, or PET-CT scans of the chest, abdomen, pelvis (optional unless known pelvic disease is present at screening), and brain (only as clinically warranted 
based on symptoms/findings). All screening tumor imaging assessments should be performed based on the subject's qualifying scan obtained within 28 days 
prior to the start of treatment. RECIST and irRC documentation to be completed at each assessment period. The same mode of imaging is required to be carried 
through each subject’s respective treatment period. 
 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
125 
Table 20: 
Schedule of Events for Maintenance Phase of Study 
 
Maintenance Phase Treatment (repeats every 2 weeks, except where noted)a 
 
 
Study Week 
1 
2 
EOT Visitb 
Unscheduled 
Visitc 
Study Day 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
 
Concomitant medications 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Physical exam, weight 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Vital signsd 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X 
ECOG performance status 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
12-lead ECG 
X 
Every 4 weeks 
X 
 
Confirm contraceptive 
measures 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse event collection 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X 
FACT-Hep 
X 
Every 4 weeks 
X 
 
Laboratory Assessments 
Chemistry panele 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
CA19-9  
X 
Every 4 weeks 
X 
 
Hematologyf 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Urinalysis 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Pregnancy testg 
X 
Every 4 weeks 
X 
 
Collect whole blood for 
immunology analysish 
X 
Every 8 weeks during routine blood draws 
X 
 
Collect whole blood for 
ctDNA/ctRNA analysish 
X 
Every 8 weeks during routine blood draws 
X 
 
Additional tumor biopsy 
May be collected at any time point, as clinically indicated at the Investigator’s discretion 
 CT, MRI, or PET-CTi 
X 
Every 12 weeks 
X 
 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
 
Confidential and Proprietary 
126 
a Subjects will remain in the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD 
or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to 
continue treatment. Any required blood draws and safety laboratory sample collections (including urinalysis) may be performed within a 3-day window of the 
time indicated.± 
b EOT visit must be performed 30 (±5 days) after the last study treatment. 
c Additional assessments performed during an unscheduled visit are at the discretion of the PI or treating physician and must be recorded in the subject’s source 
documents and on the Unscheduled Visit eCRF. 
d Vital signs of temperature, heart rate, blood pressure, and respiratory rate will be assessed at every visit. Vital signs are to be obtained after the subject has been 
in a seated resting position for at least 5 minutes and within 30 minutes prior to the start of any infusional study treatment. For visits where a subject is 
receiving an infusion of any study compounds, vital signs will be collected at the following time points in relation to the start of first infusion of the day: prior 
to infusion, 15 minutes post, 30 minutes post, and hourly until the subject is discharged. Temperature will be documented each visit at the first pre-infusion 
assessment of vital signs and subsequently if clinically indicated. 
e Chemistry panel to include laboratory assessments noted in Table 18. 
f Hematology to include CBC with differential (5 part) and platelets with hemoglobin and hematocrit. 
g Serum pregnancy test for females of child-bearing potential. 
h Blood collection for exploratory immunology and ctDNA/ctRNA analyses will be performed every 8 weeks in the maintenance phase during routine blood 
draws, and at the end-of-treatment visit.  
i Tumor imaging by CT scan, MRI, or PET-CT will be performed every 12 weeks in the maintenance phase. Evaluations may include CT, MRI, or PET-CT 
scans of the chest, abdomen, pelvis (optional unless known pelvic disease is present at screening), and brain (only as clinically warranted based on 
symptoms/findings). RECIST and irRC documentation to be completed at each assessment period. The same mode of imaging is required to be carried through 
each subject’s respective treatment period. 

NANT Pancreatic Cancer Vaccine 
NantKwest, Inc. 
Clinical Trial Protocol: QUILT-3.060 Protocol Amendment 1 
APPENDIX 1. 
SPONSOR SIGNATURE 
Study Title: 
NANT Pancreatic Cancer Vaccine: Combination 
immunotherapy with high-affinity natural killer (haNK) cell 
therapy in subjects with pancreatic cancer who have 
progressed on or after standard-of-care therapy. 
Study Number: 
QUILT-3.060 
Version Number: 
2 
Final Date: 
15 February 2018 
This clinical trial protocol was subject to critical review and has been approved by NantKwest. 
The following personnel contributed to writing and/or approving this protocol: 
JIJ'VI 
Lr C> )'\, ba./...e..,_ I(' c:JF 
John H. Lee, MD 
Date: 
Senior Vice President Adult Medical Affairs, NantKwest Inc. 
9920 Jefferson Blvd 
Culver City, CA 90232 
Email: John.Lee@Nantkwest.com 
Cell Phone: + 1-605-610-6391 
Confidential and Proprietary 
161